IN2012DN05082A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN05082A IN2012DN05082A IN5082DEN2012A IN2012DN05082A IN 2012DN05082 A IN2012DN05082 A IN 2012DN05082A IN 5082DEN2012 A IN5082DEN2012 A IN 5082DEN2012A IN 2012DN05082 A IN2012DN05082 A IN 2012DN05082A
- Authority
- IN
- India
- Prior art keywords
- prolactin receptor
- benign
- mediated
- hyperand
- cotreatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or 5 prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyperand normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block 10 prolactin receptor-mediated signaling.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09075546A EP2332995A1 (en) | 2009-12-10 | 2009-12-10 | Neutralizing prolactin receptor antibodies and their therapeutic use |
PCT/EP2010/067742 WO2011069795A1 (en) | 2009-12-10 | 2010-11-18 | Neutralizing prolactin receptor antibodies and their therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN05082A true IN2012DN05082A (en) | 2015-10-09 |
Family
ID=42091520
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN5082DEN2012 IN2012DN05082A (en) | 2009-12-10 | 2010-11-18 | |
IN5078DEN2012 IN2012DN05078A (en) | 2009-12-10 | 2010-11-18 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN5078DEN2012 IN2012DN05078A (en) | 2009-12-10 | 2010-11-18 |
Country Status (40)
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
SI2542257T1 (en) | 2010-03-01 | 2018-01-31 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
EP2530089A1 (en) * | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
KR102494534B1 (en) | 2012-03-14 | 2023-02-06 | 리제너론 파마슈티칼스 인코포레이티드 | Multispecific antigen-binding molecules and uses thereof |
US8883979B2 (en) * | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US9725515B2 (en) * | 2012-12-24 | 2017-08-08 | Abbvie Inc. | Prolactin receptor binding proteins and uses thereof |
US9023357B2 (en) | 2013-03-15 | 2015-05-05 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
US9545451B2 (en) | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
TWI641620B (en) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | Anti-prlr antibodies and uses thereof |
US10308697B2 (en) | 2014-04-30 | 2019-06-04 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
US20180148514A1 (en) | 2014-10-02 | 2018-05-31 | City Of Hope | Multivalent meditopes, meditope-binding antibodies and uses thereof |
TWI774028B (en) | 2015-01-30 | 2022-08-11 | 學校法人埼玉醫科大學 | Anti-ALK2 antibody and its use |
US11191844B2 (en) | 2015-07-06 | 2021-12-07 | Regeneran Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
IL266917B2 (en) | 2016-11-29 | 2023-10-01 | Regeneron Pharma | Anti-human prolactin receptor (prlr) antibody-drug conjugates and use thereof in combination therapy of prlr positive breast cancer |
FR3062213B1 (en) * | 2017-01-20 | 2021-02-26 | Endodiag | USE OF THE CD71 RECEIVER IN THE DETECTION AND TREATMENT OF ENDOMETRIOSIS |
TW201836647A (en) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | Anti-prlr antibody-drug conjugates (adc) and uses thereof |
EP3621618A4 (en) * | 2017-05-12 | 2021-01-27 | Millennium Pharmaceuticals, Inc. | Treatment of gastroparesis with triazaspiro(4.5)decanone |
CA3069193A1 (en) | 2017-07-10 | 2019-01-17 | Bayer Pharma Aktiengesellschaft | Prolactin receptor antibody for male and female pattern hair loss |
BR112020016005A2 (en) | 2018-02-07 | 2020-12-15 | Regeneron Pharmaceuticals, Inc. | METHOD OF ADMINISTERING A THERAPEUTIC PROTEIN TO THE CENTRAL NERVOUS SYSTEM, MULTIDOMINIUM THERAPEUTIC PROTEIN, POLYNUCLEOTIDE, GENE THERAPY VECTOR, AND USE OF A NUCLEOTIDE THAT CODES THE THERAPEUTIC PROTEIN. |
WO2019169330A1 (en) * | 2018-03-02 | 2019-09-06 | Oncolix, Inc. | Method for treating cancers expressing prolactin receptor |
CN109627340B (en) * | 2018-12-05 | 2021-02-12 | 上海交通大学 | CD3 and PRLR bispecific antibody and construction and application thereof |
US10467487B1 (en) * | 2018-12-11 | 2019-11-05 | Chongqing Jinkang New Energy Automobile Co., Ltd. | Fusion-based traffic light recognition for autonomous driving |
CN112425568A (en) * | 2020-12-11 | 2021-03-02 | 上海市计划生育科学研究所 | Method for establishing benign prostatic hyperplasia BPH dog model with EMT characteristics |
AR124681A1 (en) | 2021-01-20 | 2023-04-26 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
CN114853890B (en) * | 2022-03-16 | 2023-04-28 | 沈阳三生制药有限责任公司 | PRLR antigen binding protein and preparation method and application thereof |
CN114634574B (en) * | 2022-04-18 | 2022-12-20 | 先进生物(苏州)有限公司 | scFv antibody against B7H6, encoding gene and application thereof |
CN117285625B (en) * | 2023-11-24 | 2024-01-23 | 南京佰抗生物科技有限公司 | Anti-prolactin monoclonal antibody and application thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US4986615A (en) | 1988-10-17 | 1991-01-22 | The Vendo Company | Vending apparatus |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
GB9105245D0 (en) * | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
DE69233204T2 (en) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE |
DK1143006T3 (en) | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vectors / DNA sequences from human combinatorial antibody libraries |
WO1998010765A1 (en) * | 1996-09-13 | 1998-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Non-hormonal method of contraception |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
US6867187B2 (en) * | 2000-12-22 | 2005-03-15 | Trustees Of The University Of Pennsylvania | Composition and method for modulating somatolactogenic function |
EP1325930A1 (en) * | 2002-01-08 | 2003-07-09 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mammal prolactin variants |
EP1578480A2 (en) * | 2002-12-13 | 2005-09-28 | The Ohio State University | Antagonists for human prolactin |
GB0305790D0 (en) * | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Novel Composition |
KR101206318B1 (en) * | 2004-10-28 | 2012-11-29 | 교와 핫꼬 기린 가부시키가이샤 | Remedy for endometriosis |
WO2006089678A2 (en) * | 2005-02-22 | 2006-08-31 | Bioinvent International Ab | Antibodies and peptides binding to hiv tat, and uses thereof |
GB0517878D0 (en) * | 2005-09-02 | 2005-10-12 | Bioinvent Int Ab | Immunotherapeutic treatment |
US7422899B2 (en) | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
EP3415532A1 (en) | 2006-08-18 | 2018-12-19 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
AU2008278704A1 (en) | 2007-05-30 | 2009-01-29 | Auckland Uniservices Limited | Antibodies and sirna against growth hormone, prolactin and proliferin for use in the treatment of tumors and endometriosis |
EP2025683A1 (en) * | 2007-08-13 | 2009-02-18 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Variants of prolactin as antagonists of its receptor |
EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
WO2011139375A1 (en) * | 2010-05-06 | 2011-11-10 | Ludwig Institute For Cancer Research Ltd | Antibodies directed against carbonic anhydrase ix and methods and uses thereof |
GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
-
2009
- 2009-12-10 EP EP09075546A patent/EP2332995A1/en not_active Withdrawn
-
2010
- 2010-11-18 PT PT107822553T patent/PT2510006T/en unknown
- 2010-11-18 JP JP2012542432A patent/JP2013513361A/en active Pending
- 2010-11-18 JP JP2012542433A patent/JP2013513362A/en active Pending
- 2010-11-18 KR KR1020127017831A patent/KR101765968B1/en active IP Right Grant
- 2010-11-18 WO PCT/EP2010/067744 patent/WO2011069797A1/en active Application Filing
- 2010-11-18 EP EP10779014A patent/EP2510003A1/en not_active Withdrawn
- 2010-11-18 CN CN201080063269.4A patent/CN102884082B/en active Active
- 2010-11-18 CA CA2783678A patent/CA2783678A1/en not_active Abandoned
- 2010-11-18 MA MA34951A patent/MA33888B1/en unknown
- 2010-11-18 EP EP12192722A patent/EP2567980A1/en not_active Withdrawn
- 2010-11-18 ES ES10776753.5T patent/ES2603352T3/en active Active
- 2010-11-18 JP JP2012542431A patent/JP2013513559A/en active Pending
- 2010-11-18 CN CN201080063347.0A patent/CN102947338B/en active Active
- 2010-11-18 CA CA2783514A patent/CA2783514A1/en not_active Abandoned
- 2010-11-18 CA CA2783654A patent/CA2783654A1/en not_active Abandoned
- 2010-11-18 SI SI201031367A patent/SI2510006T1/en unknown
- 2010-11-18 WO PCT/EP2010/067743 patent/WO2011069796A1/en active Application Filing
- 2010-11-18 AU AU2010330161A patent/AU2010330161B2/en active Active
- 2010-11-18 LT LTEP10776753.5T patent/LT2510002T/en unknown
- 2010-11-18 US US13/514,994 patent/US20120315276A1/en not_active Abandoned
- 2010-11-18 IN IN5082DEN2012 patent/IN2012DN05082A/en unknown
- 2010-11-18 EP EP10776753.5A patent/EP2510002B1/en active Active
- 2010-11-18 NZ NZ600511A patent/NZ600511A/en unknown
- 2010-11-18 ME MEP-2016-244A patent/ME02577B/en unknown
- 2010-11-18 RS RS20160915A patent/RS55277B1/en unknown
- 2010-11-18 SI SI201031312A patent/SI2510002T1/en unknown
- 2010-11-18 PE PE2017000782A patent/PE20171134A1/en unknown
- 2010-11-18 CN CN2010800634488A patent/CN102858803A/en active Pending
- 2010-11-18 WO PCT/EP2010/067746 patent/WO2011069798A1/en active Application Filing
- 2010-11-18 EP EP10781671A patent/EP2510004A1/en not_active Withdrawn
- 2010-11-18 EP EP10784482A patent/EP2510007A1/en not_active Withdrawn
- 2010-11-18 JP JP2012542435A patent/JP2013513364A/en not_active Ceased
- 2010-11-18 US US13/514,995 patent/US20130022606A1/en not_active Abandoned
- 2010-11-18 WO PCT/EP2010/067742 patent/WO2011069795A1/en active Application Filing
- 2010-11-18 JP JP2012542434A patent/JP2013513363A/en active Pending
- 2010-11-18 CN CN201080063268XA patent/CN102858801A/en active Pending
- 2010-11-18 EP EP12192707A patent/EP2570435A1/en not_active Withdrawn
- 2010-11-18 US US13/514,992 patent/US9649374B2/en active Active
- 2010-11-18 PE PE2012000797A patent/PE20121561A1/en not_active Application Discontinuation
- 2010-11-18 SG SG2012041166A patent/SG181511A1/en unknown
- 2010-11-18 CN CN2010800633485A patent/CN102741291A/en active Pending
- 2010-11-18 PE PE2012000791A patent/PE20121360A1/en not_active Application Discontinuation
- 2010-11-18 LT LTEP10782255.3T patent/LT2510006T/en unknown
- 2010-11-18 HU HUE10782255A patent/HUE030143T2/en unknown
- 2010-11-18 US US13/514,993 patent/US20130171147A1/en not_active Abandoned
- 2010-11-18 CA CA2783651A patent/CA2783651A1/en not_active Abandoned
- 2010-11-18 EP EP10781882A patent/EP2510005A1/en not_active Withdrawn
- 2010-11-18 WO PCT/EP2010/067740 patent/WO2011069794A1/en active Application Filing
- 2010-11-18 EA EA201200860A patent/EA028678B1/en not_active IP Right Cessation
- 2010-11-18 CA CA2783513A patent/CA2783513C/en active Active
- 2010-11-18 AP AP2012006343A patent/AP2012006343A0/en unknown
- 2010-11-18 MX MX2012006620A patent/MX339343B/en active IP Right Grant
- 2010-11-18 AU AU2010330165A patent/AU2010330165B2/en active Active
- 2010-11-18 IN IN5078DEN2012 patent/IN2012DN05078A/en unknown
- 2010-11-18 PT PT107767535T patent/PT2510002T/en unknown
- 2010-11-18 SG SG2012041182A patent/SG181513A1/en unknown
- 2010-11-18 KR KR1020127017833A patent/KR101790366B1/en active IP Right Grant
- 2010-11-18 JP JP2012542436A patent/JP6066474B2/en active Active
- 2010-11-18 EP EP12192708A patent/EP2567979A1/en not_active Withdrawn
- 2010-11-18 PL PL10776753T patent/PL2510002T3/en unknown
- 2010-11-18 PL PL10782255T patent/PL2510006T3/en unknown
- 2010-11-18 ES ES10782255.3T patent/ES2610654T3/en active Active
- 2010-11-18 EA EA201200851A patent/EA029327B1/en not_active IP Right Cessation
- 2010-11-18 NZ NZ600512A patent/NZ600512A/en unknown
- 2010-11-18 WO PCT/EP2010/067747 patent/WO2011069799A1/en active Application Filing
- 2010-11-18 EP EP12192705A patent/EP2567978A1/en not_active Withdrawn
- 2010-11-18 US US13/514,996 patent/US9241989B2/en active Active
- 2010-11-18 EP EP12192721A patent/EP2570436A1/en not_active Withdrawn
- 2010-11-18 EP EP10782255.3A patent/EP2510006B1/en active Active
- 2010-11-18 US US13/514,991 patent/US20120321632A1/en not_active Abandoned
- 2010-11-18 RS RS20170010A patent/RS55589B1/en unknown
- 2010-11-18 BR BR112012015852A patent/BR112012015852B8/en active IP Right Grant
- 2010-11-18 HU HUE10776753A patent/HUE031631T2/en unknown
- 2010-11-18 DK DK10782255.3T patent/DK2510006T3/en active
- 2010-11-18 MX MX2012006621A patent/MX2012006621A/en unknown
- 2010-11-18 DK DK10776753.5T patent/DK2510002T3/en active
- 2010-11-18 CN CN2010800634492A patent/CN102858804A/en active Pending
- 2010-11-18 EP EP12192704A patent/EP2567977A1/en not_active Withdrawn
- 2010-11-18 CA CA2783610A patent/CA2783610C/en active Active
- 2010-12-10 AR ARP100104563A patent/AR079348A1/en active IP Right Grant
- 2010-12-10 AR ARP100104564A patent/AR079349A1/en unknown
- 2010-12-10 AR ARP100104566A patent/AR079351A1/en unknown
- 2010-12-10 TW TW099143330A patent/TW201130506A/en unknown
- 2010-12-10 TW TW099143327A patent/TW201130504A/en unknown
- 2010-12-10 TW TW099143332A patent/TWI508744B/en active
- 2010-12-10 AR ARP100104567A patent/AR079352A1/en active IP Right Grant
- 2010-12-10 TW TW099143326A patent/TW201138817A/en unknown
- 2010-12-10 TW TW099143328A patent/TWI487536B/en active
- 2010-12-10 AR ARP100104565A patent/AR079350A1/en unknown
- 2010-12-17 AR ARP100104707A patent/AR079641A1/en unknown
-
2012
- 2012-06-04 IL IL220151A patent/IL220151A0/en active IP Right Grant
- 2012-06-04 IL IL220149A patent/IL220149A/en active IP Right Grant
- 2012-06-07 CU CU2012000092A patent/CU20120092A7/en unknown
- 2012-06-07 CU CU2012000093A patent/CU23973B1/en not_active IP Right Cessation
- 2012-06-08 CR CR20120310A patent/CR20120310A/en unknown
- 2012-06-08 DO DO2012000160A patent/DOP2012000160A/en unknown
- 2012-06-08 CL CL2012001539A patent/CL2012001539A1/en unknown
- 2012-06-08 CL CL2012001540A patent/CL2012001540A1/en unknown
- 2012-06-08 EC ECSP12011965 patent/ECSP12011965A/en unknown
- 2012-06-08 TN TNP2012000294A patent/TN2012000294A1/en unknown
- 2012-06-08 GT GT201200186A patent/GT201200186A/en unknown
- 2012-06-08 ZA ZA2012/04214A patent/ZA201204214B/en unknown
- 2012-06-08 DO DO2012000159A patent/DOP2012000159A/en unknown
- 2012-06-08 EC ECSP12011966 patent/ECSP12011966A/en unknown
- 2012-06-08 CR CR20120312A patent/CR20120312A/en unknown
- 2012-06-08 ZA ZA2012/04213A patent/ZA201204213B/en unknown
-
2013
- 2013-07-02 HK HK13107690.3A patent/HK1180354A1/en unknown
- 2013-07-10 HK HK13108063.0A patent/HK1180700A1/en unknown
-
2015
- 2015-07-03 JP JP2015134286A patent/JP6199930B2/en active Active
-
2016
- 2016-10-26 HR HRP20161401TT patent/HRP20161401T1/en unknown
- 2016-10-31 CY CY20161101101T patent/CY1118209T1/en unknown
-
2017
- 2017-01-05 HR HRP20170016TT patent/HRP20170016T1/en unknown
- 2017-01-10 CY CY20171100030T patent/CY1118407T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN05082A (en) | ||
TN2013000501A1 (en) | Neutralizing prolactin receptor antibody mat3 and its therapeutic use | |
CY1118608T1 (en) | ANTIBODIES FOR CLAUDINE-expressing CANCER 6 | |
MX338217B (en) | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and use thereof for treating diseases. | |
EA201491344A1 (en) | SPYROINDOLINE DERIVATIVES AS ANTAGONISTS OF THE GORADONE GONADOTROPYN-REALIZING RECEPTOR | |
WO2011098437A3 (en) | Progesterone receptor antagonists | |
WO2011009534A3 (en) | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases | |
ATE460412T1 (en) | TRIS-SUBSTITUTED THIOPHENES AS PROGESTERONE RECEPTOR MODULATORS | |
MX2022008265A (en) | Compounds and methods for treatment of visceral pain. | |
EA201501000A1 (en) | SPYROINDOLINE DERIVATIVES FOR APPLICATION AS ANTAGONISTS OF GONADOTROPIN-REALIZING HORMONE RECEPTOR ANTAGONISTS |